The Fate of FDA Authority: Addressing Recent Supreme Court Decisions on Mifepristone, Chevron, and Beyond

Recorded July 11, 2024   On-Demand Webinar


In this webinar, we will explore recent Supreme Court decisions impacting FDA’s regulatory authority and the subsequent repercussions for regulated industry. Our panel of experts will review the unanimous decision in the case that challenged FDA’s ability to approve the abortion medication mifepristone (FDA v. Alliance for Hippocratic Medicine), as well as the cases that challenged the Chevron doctrine, where courts deferred to an agency’s interpretation of an ambiguous statute (Loper Bright Enterprises v. Raimondo and Relentless, Inc. v. Department of Commerce). Don’t miss the opportunity to stay informed and prepared with critical information for navigating the future of FDA authority.


Kalah Auchincloss | Read Bio
Principal and Deputy General Counsel, ELIQUENT Life Sciences

Vanessa K. Burrows | Read Bio
Partner, Simpson Thacher & Bartlett LLP

Chad A. Landmon | Read Bio
Shareholder, Polsinelli PC

Moderated by
Stacy Cline Amin | Read Bio
Partner, Morrison & Foerster LLP

Buy Now